Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VISUgican
- Development stage
- Unknown
- Lead developer
- Visufarma
- Modality
- Implantable Hydrogels → Hydrogel Systems → Drug Delivery Systems, Small Molecules, Non-biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Injectable Hydrogels → Hydrogel Systems → Drug Delivery Systems
- Administration
- Ophthalmic
01
Overview
VISUgican is a sterile ophthalmic solution developed by VISUfarma (acquired by Lupin) for the treatment of dry eye syndrome and the protection of the ocular surface. The formulation is a combination of sodium hyaluronate, Coenzyme Q10 (ubiquinone), and Vitamin E TPGS (tocofersolan). Sodium hyaluronate acts as a lubricant and humectant, stabilizing the tear film and providing long-lasting hydration to the corneal surface. Coenzyme Q10 serves as a potent antioxidant, protecting ocular tissues from oxidative stress and promoting the healing of corneal micro-lesions. Vitamin E TPGS acts as a surfactant and antioxidant that enhances the solubility and bioavailability of Coenzyme Q10. VISUgican is particularly indicated for patients with moderate to severe dry eye, corneal sensitivity, or those recovering from ophthalmic surgeries such as LASIK or cataract extraction.
- Brand names
- VISUgican
- Other names
- VISUgican eye drops
02
Targets
CD44 (CD44 antigen)
Beyond the preview
Go deeper on VISUgican.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VISUgican.